75 patents in this list

Updated:

Metabolic disorders affect critical pathways in human biochemistry, leading to conditions like type 2 diabetes, where blood glucose levels regularly exceed 180 mg/dL, or hyperuricemia, where serum uric acid rises above 7.0 mg/dL. These disruptions often stem from complex interactions between genetic predisposition, diet, and alterations in the gut microbiome.

The challenge lies in developing targeted probiotic interventions that can modulate specific metabolic pathways while maintaining stability and viability through the digestive tract.

This page brings together solutions from recent research—including engineered Lactobacillus strains for glucose regulation, bacteria expressing therapeutic proteins for autoimmune diabetes, and novel probiotic delivery systems for treating hyperuricemia. These and other approaches focus on practical therapeutic applications that can be translated into clinical treatments for metabolic disorders.

1. Microbial Consortia with Active and Supportive Microbes for Substrate Degradation and Metabolism

Federation Bio Inc., 2023

Microbial consortia for effectively treating conditions related to metabolic disease by efficiently breaking down and metabolizing disease-associated substrates. The consortia contain a group of active microbes that degrade the substrate causing the disease, along with a supportive community of microbes that optimize the active microbes' growth and metabolism. The supportive community enhances characteristics like engraftment, biomass, stability of the active microbes. The consortium can degrade substrates like phenylalanine, tyrosine, bile acids, and pathogenic carbohydrates.

US20230125976A1-patent-drawing

2. Composition of Inactivated Lactobacillus casei I0B-P9 and Postbiotics

Tianjin InnoOrigin Biological Technology Co., Ltd., 2023

Using inactivated Lactobacillus casei I0B-P9 and its postbiotics to reduce blood glucose and improve dyslipidemia in diabetics.

3. Microbiota Modulation Method Using Customized Probiotic and Prebiotic Compositions

SOLAREA BIO, INC., 2023

A method for treating type 2 diabetes (T2D) by modulating a subject's microbiota composition away from that associated with a Western diet and toward one conferring the benefits of a plant-based diet. The method involves administering probiotics and prebiotics to improve the gut microbiome, with strains shown to be beneficial in studies of diabetes and obesity. The microbial compositions can be customized based on an individual's microbiome profile and contain specific bacteria and fungi identified from plants.

4. Lactobacillus rhamnosus CMU-pb-7 Strain for Modulation of Liver Lipid Metabolism and Antioxidant Enhancement

Guangdong Xinghai Biotechnology Co., Ltd., Guangdong Xinghai Institute of Cell, 2023

Using a specific strain of Lactobacillus rhamnosus called CMU-pb-7 isolated from feces, to prepare blood lipid-lowering drugs. The strain can relieve impaired glucose tolerance caused by a high-fat diet in mice with hyperlipidemia, reduce the blood lipid level, enhance the antioxidant capacity of the liver tissue, and regulate the expression of key proteins of liver lipid metabolism to relieve fatty change caused by a high-fat diet.

5. Compositions Containing Lactobacillus fermentum TSF331 and Lactobacillus reuteri TSR332

GLAC BIOTECH CO., LTD., 2023

Food or pharmaceutical compositions with specific strains of lactic acid bacteria (Lactobacillus fermentum TSF331 and Lactobacillus reuteri TSR332) that can be used to reduce blood uric acid concentration. The compositions can be administered to help prevent and treat conditions like hyperuricemia and gout. The compositions contain strains that have been shown to degrade purine and lower uric acid levels.

US11785975B2-patent-drawing

6. Genetically Modified Lactic Acid Bacteria Expressing IL-2 and Type 1 Diabetes-Specific Antigen

INTREXON ACTOBIOTICS N.V., 2023

Compositions and methods for treating type 1 diabetes using genetically modified lactic acid bacteria expressing IL-2 and a type 1 diabetes-specific antigen. The bacteria are orally administered to deliver low-dose IL-2 and antigen to the gut mucosa, stimulating regulatory T cells to suppress autoimmunity and reverse established type 1 diabetes.

7. Genetically Engineered Bacteria Expressing Modified Phenylalanine Ammonia Lyase Enzyme

Synlogic Operating Company, Inc., 2023

Genetically engineered bacteria that can reduce hyperphenylalaninemia in mammals like humans. The bacteria are designed to produce a modified version of the enzyme phenylalanine ammonia lyase (PAL) that better metabolizes phenylalanine. This allows the bacteria to break down excess phenylalanine in the gut and reduce blood levels. It could offer a novel treatment option for phenylketonuria (PKU) and other disorders associated with high phenylalanine. The engineered bacteria may be orally administered to provide a long-term, natural protein-friendly approach to reducing phenylalanine.

8. Microorganism Mixture Compositions with Specific Strains Modulating Uricase and Xanthine Oxidase Activity

BEO THERAPEUTICS, 2023

Compositions containing a mixture of microorganisms like bacteria, yeasts, and fungi for reducing blood urate levels as a treatment and prevention strategy for urate-related diseases like gout and hyperuricemia. The compositions aim to balance the gut microbiota by increasing uricase activity and reducing xanthine oxidase activity. This can be achieved using specific strains that inhibit xanthine oxidase and/or express uricase.

US20230285477A1-patent-drawing

9. Lactobacillus plantarum Strain MG4229 with Acid and Bile Tolerance and Enzyme Production

Mediogen Co., Ltd., 2023

A Lactobacillus plantarum strain that can lower blood glucose levels and has antioxidant activity. It's used in compositions like food, medical, and cosmetic products to help prevent and treat diabetes and provide antioxidant benefits. The strain, Lactobacillus plantarum MG4229, is isolated from food and has characteristics like acid and bile tolerance, hydrophobicity, and enzyme production.

US11738057B2-patent-drawing

10. Composition Containing Lactobacillus plantarum ATG-K2 or ATG-K6 Strains from Fermented Vegetables

ATOGEN CO., LTD., 2023

A composition for preventing and treating lipid-related metabolic diseases such as fatty liver, diabetes, and obesity. It contains Lactobacillus plantarum ATG-K2 or ATG-K6 strains isolated from fermented vegetables. The composition can be used as a health supplement or functional food to improve markers of liver health, lipid metabolism, obesity, and diabetes. It provides a natural and effective treatment option for lipid-related metabolic disorders.

11. Desulfovibrio Bacteria and 6-Bromotryptophan Metabolites for Modulating Inflammation

ACADEMISCH MEDISCH CENTRUM, WAGENINGEN UNIVERSITEIT, 2023

Using certain bacteria and their metabolites to prevent or treat inflammation-related diseases like diabetes, autoimmune conditions, cardiovascular disease, and inflammatory disorders. The specific bacteria are Desulfovibrio species like Desulfovibrio piger, and the metabolites include 6-bromotryptophan. Administering these agents can reduce inflammation and severity of these diseases.

US20230181531A1-patent-drawing

12. Probiotic Compositions Containing Specific Gut Bacterial Strains

DUPONT NUTRITION BIOSCIENCES APS, 2023

Probiotic compositions and methods for improving metabolic health and preventing obesity related disorders. The compositions contain specific strains of gut bacteria including Eubacterium eligens, Intestinimonas massiliensis, Prevotella copri, and certain Akkermansia species. Administering these compositions can help treat or prevent obesity, diabetes, metabolic syndrome and related conditions.

US20230181653A1-patent-drawing

13. Lactobacillus Strains LMT15-14 and LMT19-1 with Extracts Exhibiting Modulation of Lipid Metabolism in Liver and Fat Cells

MEDYTOX INC., 2023

Microorganisms and extracts thereof that reduce liver fat content, inhibit lipogenesis, promote fat oxidation, reduce body fat, and increase AMPK phosphorylation when contacted with liver or fat cells. The microorganisms are Lactobacillus strains LMT15-14 and LMT19-1.

14. Nutritional Composition with Bifidobacterium breve and Non-Digestible Oligosaccharides for Infant Formula

N.V. Nutricia, 2023

Feeding infants a nutritional composition containing Bifidobacterium breve and non-digestible oligosaccharides early in life to prevent metabolic disorders like fatty liver disease, hypercholesterolemia, and atherosclerosis later in life. The composition promotes healthy lipid metabolism and liver function when challenged with a high fat diet by modulating gene expression pathways. The Bifidobacterium breve probiotic and oligosaccharides combination can be added to infant formula to mimic breast milk benefits for long-term metabolic health.

15. Infant Nutritional Composition with Bifidobacterium Breve and Non-Digestible Oligosaccharides

N.V. Nutricia, 2023

Early life nutritional intervention to prevent obesity, diabetes and chronic inflammation. Administering bifidobacterium breve and non-digestible oligosaccharides to infants results in lower insulin levels, improved insulin sensitivity, and reduced inflammation when challenged with a Western diet later in life. The combination programs infants to better withstand risks associated with a Western diet, preventing hyperinsulinemia, insulin resistance, diabetes, and chronic inflammation.

16. Lactobacillus Plantarum Strain with Inhibition of Adipose and Liver Fat Accumulation

GI BIOME, 2023

A Lactobacillus Plantarum strain (Accession No. KCTC 14107BP) that can inhibit fat accumulation in white adipose tissue, brown adipose tissue, and liver tissue. The strain also reduces blood glucose levels, improves glucose tolerance, and ameliorates insulin resistance.

US20230111353A1-patent-drawing

17. Compositions of Specific Lactic Acid Bacteria Strains for Blood Glucose Modulation

GLAC BIOTECH CO., LTD., 2023

Food and pharmaceutical compositions containing specific strains of lactic acid bacteria that can modulate blood glucose levels and help prevent and treat diabetes. The compositions contain strains of Lactobacillus reuteri, Lactobacillus salivarius, Lactobacillus acidophilus, and Lactobacillus johnsonii. Administering these compositions can help lower blood glucose levels. The strains have been deposited in culture collections.

US11612171B2-patent-drawing

18. Bacterial Probiotics Producing Aryl Hydrocarbon Receptor Agonists for Modulating Metabolic Pathways

INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, 2023

Using bacterial probiotics that produce AhR receptor agonists to prevent and treat metabolic syndrome and obesity. The probiotics stimulate the Aryl hydrocarbon receptor (AhR) pathway which is impaired in metabolic syndrome. AhR agonists improve weight, glucose control, and fatty liver disease in animal models of obesity. The agonists also show promise in human studies. The invention involves using AhR agonist-producing probiotics or AhR agonists themselves to activate the pathway and treat metabolic syndrome and obesity.

US11596657B2-patent-drawing

19. Microbial Compositions with Enhanced Butyrate Production for Microbiome Modulation

PENDULUM THERAPEUTICS, INC., 2023

Microbe-based therapies for treating disorders like neurological and metabolic conditions, by modulating the microbiome to produce beneficial metabolites like SCFAs. The therapies involve administering purified populations of microbes that increase butyrate production in the subject. The microbes can modulate neural, hormonal, and metabolic pathways to treat the disorders. The compositions can be administered orally in pill form and are useful after antibiotic treatments to restore a healthy microbiome. The compositions can be customized based on a subject's microbiome sequencing.

US11583558B2-patent-drawing

20. Oral Composition Containing Pediococcus acidilactici Strain for Blood Glucose Modulation

GENBIOMA APLICACIONES, S.L., 2023

Using the bacterium strain Pediococcus acidilactici to regulate blood glucose levels and prevent or treat hyperglycemia. Administering this bacterium orally in a composition as a probiotic has been shown to lower blood glucose levels and prevent hyperglycemia in animal models.

US20230038352A1-patent-drawing

21. Lactobacillus fermentum Strain KCTC 14106BP with Unique Modulation of Adipose Tissue and Glucose Metabolism

22. Composition Comprising Propionibacterium freudenreichii for Enhanced Intestinal Propionic Acid Production

23. Composition Comprising Lactobacillus plantarum L-137 with Applications in Metabolic Modulation

24. Bacterial Strain Administration for Modulation of Gut Microbiome in Type 2 Diabetes

25. Lactobacillus fermentum Strain KCTC 14105BP with Fat Accumulation Reduction and Insulin Sensitivity Enhancement Properties

Get Full Report

Access our comprehensive collection of patents related to this technology